Drug intelligence / Profile preview

tubacin

Development stage
Preclinical
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

**Tubacin** is a highly potent, selective, reversible, and cell-permeable small molecule inhibitor of **histone deacetylase 6 (HDAC6)**. Tubacin increases acetylation of α-tubulin without significantly affecting histone acetylation, thereby influencing processes such as microtubule dynamics, intracellular transport, and protein degradation. It has a strong antiproliferative and pro-apoptotic effect in various cancer cell lines, and enhances the effects of other anticancer drugs. Tubacin is primarily used as a research chemical probe for HDAC6 due to its poor drug-like properties, including high molecular weight and lipophilicity, which limit in vivo utility[2][3][4][6][7].

Other names
Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-N-[4-[(2R,4R,6S)-4-[[4,5-di(phenyl)-1,3-oxazol-2-yl]sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide
02

Targets

HDAC6 (Histone deacetylase 6)

Beyond the preview

Go deeper on tubacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tubacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call